Icon boosts biorepository capabilities to meet personalised med demands

- Last updated on GMT

Icon boosts biorepository capabilities
Icon has doubled its sample storage capacity through an expansion at its New York facility.

The expansion – at the central lab in Farmingdale – means the Irish contract research organisation (CRO) can now perform end-to-end biospecimen management services across a drug’s entire lifecycle.

The facility can also store specimens such as plasma, serum, whole blood, RNA, DNA, peripheral blood mononuclear cell (PBMC), urine and tissue at frozen storage conditions and liquid nitrogen.

An increase in personalised medicine development was listed as a major reason for the investment.

Tom O’Leary, president of the central laboratories said: “We believe that long-term preservation of samples is essential for the future of drug development, in particular for personalised medicine strategies that foresee an ever-increasing need for downstream analysis.

“The co-location of our biorepository services with our central labs in North America, Europe, Singapore and India is critical, as it allows for future analysis while minimising the risks and costs associated with transporting samples.“

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers